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CXCR4 Antagonism to Treat Delayed Fracture Healing
Richard Meeson, PhD,1,2 Anita Sanghani-Keri, PhD,1 Melanie Coathup, PhD,1,3 and Gordon Blunn, PhD1,4
A significant number of fractures develop nonunion. Stem cell homing is regulated through stromal cell-derived
factor 1 (SDF1) and its receptor CXCR4. Stem/progenitor cell populations can be endogenously mobilized by
administering growth factors with a pharmacological antagonist of CXCR4, AMD3100, which may be a means
to improve fracture healing. A 1.5mm femoral osteotomy in Wistar rats was stabilized with an external fixator.
Rats were pretreated with phosphate buffered saline [PBS(P)], vascular endothelial growth factor [VEGF(V)],
insulin-like growth factor-1 [IGF1(I)], or granulocyte colony stimulating factor [GCSF(G)] before AMD3100.
A control group (C) did not receive growth factors or AMD3100. Bone formation after 5 weeks was analyzed.
Group P had a significant increase in total bone volume (BV) ( p = 0.01) and group I in percentage bone in the
fracture gap ( p= 0.035). Group G showed a decrease in BV. All treated groups had an increase in trabecular
thickness. Histology showed decreased cartilage tissue associated with increased bone in groups with improved
healing, and increased fibrous tissue in poorly performing groups. Antagonism of SDF1-CXCR4 axis can boost
impaired fracture healing. AMD3100 given alone was the most effective means to boost healing, whereas
pretreatment with GCSF reduced healing. AMD3100 is likely mobilizing stem cells into the blood stream that
home to the fracture site enhancing healing.
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Impact Statement
Currently*10% of fractures progress to delayed or nonunion with significant morbidity and economic impact. Endogenous
mobilization of stem cells by pharmacological antagonism of their homing and migration receptor CXCR4 with AMD3100
experimentally reduced delayed union development. Endogenous mobilization may, therefore, translate as a low risk means
to boost healing and could potentially be given as a prophylaxis to patients with fractures at risk of delayed healing or
nonunion. These patients may include fragility fractures, comminuted tibial fractures, or when treating established non-
unions. This approach could have promise for other conditions that may benefit from stem cell treatments.
Introduction
Asignificant number of bone defects and fracturesdo not heal,1 with estimates of *100,000 fractures per
year developing nonunion in the United States.2 To achieve
bone union, there is a need to recruit a range of cells,
including inflammatory cells, endothelial cells, and stem
cells, from a range of tissue sources, including muscle,
bone marrow, adipose tissue, and periosteum.3 At rest there
are low basal levels of peripherally circulating skeletal
progenitors; *1 per 106–8 blood mononuclear cells,4–6
whereas the numbers of levels of mesenchymal stem cells
(MSCs)7 and endothelial progenitor cells (EPCs)8 in the
blood stream increase postbone fracture. The chemokine
stromal cell-derived factor 1 (SDF1; also known as CXCL12)
and its receptor CXCR4 have a key role in stem cell mi-
gration from the bone marrow stroma into the circulation and
are believed to be important for homing of stem cells to a
fracture site.9 Local increases in SDF1 expression have
been measured in distraction osteogenesis, stress fractures,
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and segmental defects.10–12 Parabiotic studies have dem-
onstrated that labeled stem cell mobilization is from the
bone marrow through the peripheral circulation and these
cells are able to then contribute to the fracture healing
process.13,14
Mobilization of hematopoietic stem cells is a mainstay of
clinical bone marrow transplantation to treat a range of
blood-related malignancies, and granulocyte colony stimu-
lating factor (GCSF) was the first growth factor used for this
purpose.15 A highly selective high-affinity competitive an-
tagonist of the CXCR4 receptor, AMD3100,16 commercially
known as Mozibil, rapidly mobilizes high numbers of
hematopoietic stem cells by blocking their interaction with
SDF1 in the marrow niche.17–19 It has been shown in mice
that when AMD3100 is given after pretreatment with vas-
cular endothelial growth factor (VEGF) rather than GCSF,
there is preferential mobilization of a population of MSCs
and EPCs relative to hematopoietic stem cells.20
To date, a few groups have started to investigate mobi-
lization of stem cells to augment bone healing. Critical-sized
calvarial defects have shown enhanced healing with 15 daily
injections of AMD3100 in mice,21 and a single dose of
AMD3100 was also shown to improve intramedullary tra-
becular bone reformation.22 For evaluation of diaphyseal
long bone healing, Kumar and Ponnazhagan23 mobilized
MSCs by pretreatment with insulin-like growth factor-1
(IGF1) followed by AMD3100, in a coapted mouse tibial
segmental fracture, and showed a significant increase in
bone mineral density. AMD3100 has also been evaluated
after creating an ‘‘Einhorn style’’ mouse femoral fracture
stabilized with a single intramedullary pin, and fracture
healing was accelerated.24
None of the aforementioned studies allow for direct
comparison of the different protocols, and neither do they
test the effect of endogenous mobilization in a translation-
ally relevant delayed union model. Therefore, based on
current literature, this study aimed to compare different
mobilization protocols (AMD3100 alone, or after pretreat-
ment with GCSF, IGF1, or VEGF) in a biomechanically
controlled, delayed union fracture model, of a rat femoral
osteotomy stabilized using an external fixator.25 The hy-
pothesis was that antagonism of the SDF1/CXCR4 axis
using ADM3100 would improve bone healing in a delayed
union fracture model, and pretreatment with IGF1 or VEGF
before AMD3100 would have the greatest efficacy due to
their preferential MSC mobilization.
Methodology
Growth factor and AMD3100 preparation
AMD3100 octahydrochloride hydrate (A5602; Sigma-
Aldrich, UK) stock solution was prepared by dissolving
5mg lyophilized product in 0.5mL sterile water, then added
to 4.5mL phosphate buffered saline (PBS) to produce a 1mg/
mL injection solution, which was aliquoted and stored at
-20C until needed. Rat VEGF 165 (400-31; PeproTech,
Rocky Hill, NJ) was prepared by dissolving the lyophilized
product in sterile water to make a 0.1mg/mL stock solution
and then 1mL of stock solution was added to 4mL of sterile
PBS +0.1% bovine serum albumin (BSA) (A9418; Sigma-
Aldrich) to achieve 100mg/mL injectable solution, which was
aliquoted and stored at -20C until needed. Recombinant
human IGF1 (100-11; PeproTech) and murine GCSF
(250-05; PeproTech) were prepared in the same manner.
Finally, PBS +0.1% BSA, ‘‘sham growth factor,’’ to de-
termine the effects of AMD3100 alone was also prepared.
Fracture model
A total of 12- to 14-week-old female Wistar rats (230–
300 g) were randomly assigned to one of the five groups:
PBS+AMD3100 (n = 6; PBS-AMD), VEGF+AMD3100
(n= 8; VEGF-AMD), IGF1+AMD3100 (n= 6; IGF1-AMD),
GCSF+AMD3100 (n= 6; GCSF-AMD), and non-mobilized
control fracture group (n= 7). A linear type 1a micro-external
fixator, with titanium blocks and carbon fiber bars was placed
on the left craniolateral femur after a lateral surgical ap-
proach.25 Using a precision guide, four bicortical 1.4mm
diameter end-threaded self-tapping stainless steel pins were
placed in predrilled 1.0mm holes. Consistent proximodistal
positioning was based on the distal extent of the greater
trochanter. Pins were exited through separate skin incisions
and the custom variable spacing fixator was attached.25
A mid-diaphyseal femoral osteotomy with no periosteal
stripping was made using a diamond tipped handsaw, while
applying sterile saline coolant/lubricant. A precision spacer
ensured a fixed distance between the cis cortex and con-
necting blocks of 9mm. The fixator was then used to distract
the osteotomy gap to 1.5mm using a second precision
spacer. The biceps femoris was closed over the osteotomy
with a single horizontal mattress suture (1.5M PDS II;
Ethicon, UK), and then the skin was closed with intradermal
continuous suture (1.5M Monocryl; Ethicon). Activity was
unrestricted postsurgery. In two rats the surgical wounds
failed to heal and were removed from the study, leaving
n = 5 for both the GCSF-AMD and PBS-AMD groups.
Twenty-four hours postsurgery, rats were given a single
intraperitoneal (i.p.) injection of either VEGF, IGF1, GCSF,
or PBS once daily for 4 days at 100 mg/kg.20 On day 5, they
were given a single injection of AMD3100 at 5mg/kg.20–24
All i.p. injections, including AMD3100 and sham PBS, were
administered at a volume of 0.5mL/100g bodyweight based
on the day 0 presurgical weight. Rats were sacrificed at 5
weeks postoperatively. All procedures were carried out with
the local Animal Welfare and Ethical Review Body approval
under personal and project licenses issues by the UK Home
Office under the 1986 Animal Scientific Procedures Act.
Microcomputed tomography and radiographic analysis
The left femur with the fixator in place was retrieved. To
reduce microcomputed tomography (microCT) beam-
hardening artifact generated from the interaction of the X-
ray beam and the metallic implant, a radiolucent PEEK
fixator block was connected externally to the fixator pins
after careful removal of the skin with surrounding soft tis-
sues, and then without disturbing the fracture callus the ti-
tanium block fixator was then removed. Samples were fixed
in 10% buffered formaldehyde for up to 3 days. The
formalin-fixed samples were wrapped in cling film to pre-
vent dehydration and mounted into a sample holder for
microCT scanning. Samples were scanned using a Bruker
Skyscan 1172 microtomograph machine (Bruker, Belgium),
at 60 kV, 167mA with a 0.5mm aluminum filter. A rotation
step of 0.5, without frame averaging, and an image pixel
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size of 4.89 mm was used. A single image capture image was
taken with the image intensification ‘‘scout’’ before scan-
ning, for two-dimensional (2D) radiographic assessment of
the osteotomy union. Radiographic scouts were randomized
and blinded to score the general impression of healing ac-
cording to the AO-ASIF recommendations for long bone
fractures; united, not united, or uncertain26 as follows: un-
united where there was no mineralized tissue bridging be-
tween the ends of the osteotomy; uncertain where there was
new bone formation; however, a radiolucent line remained
between the proximal and distal segments, and not united
where no gap between bone ends was visible.
MicroCT scans were reconstructed using NRecon
(Bruker) with smoothing = 2, ring artifact reduction = 12%
and beam hardening artifact = 41%. Analysis was per-
formed with CTAn (Bruker). Using the measuring tool, the
center point of the osteotomy was determined and the
transverse slice at that point was selected as the reference
slice. The central 60% of the osteotomy gap, that is, only
new bone formation within the osteotomy was analyzed.
The callus was isolated using a 2D region of interest shrink
wrap stretching over holes <40 pixels, despeckled <150
voxels, and then three-dimensional (3D) analysis was
performed.
Histology preparation
Bones were decalcified in a 12.5% solution of ethylene-
diaminetetraacetic acid and sequentially dehydrated for
24 h, followed by defatting with chloroform for 48 h and
then embedded into wax, with the fixator pins orthogonal to
the facing surface of the block. Fixator blocks and pins were
removed once the wax had set and a microtome (Thermo-
Fisher Scientific, UK) was used to make 5mm thick slices.
The alignment of the blocks within the microtome was al-
tered as necessary to ensure a central sagittal slice through
the femur. The position of a mid-sagittal section through the
fracture gap was assessed using the fixator pin tract holes.
Wax slices were mounted onto positively charged glass
slides (X-tra; Leica Biosystems, UK), dewaxed, and then
hydrated. Samples were then stained with hematoxylin
(Sigma-Aldrich) nuclear stain for 5min. Excess stain was
removed by gently washing with water for 5min. Slides
were counterstained in 1% eosin (Sigma-Aldrich) for 4min
and then washed and dehydrated in increasing concentra-
tions of alcohol. Slides were cleaned in xylene and mounted
under 40mm coverslips using Pertex Mounting Medium
(CellPath plc, UK).
Histomorphometric analysis
Slides were observed under a light microscope (KS-
300 Zeiss, UK). Histomorphometric analysis using the
2.5 · objective was performed on the most central slice,
using a line-intercept method with a grid scaled to the
graticule and drawn using PowerPoint (Microsoft, USA).
The grid covered the entire visual field from top to bottom
(lateral to medial cortex) and was centered over the os-
teotomy; its width was equivalent to the original 1.5mm
osteotomy. Grid ‘‘density’’ was 120 intersections and grid
squares were 160 mm in both directions. Intersections were
then scored as bone, cartilage, fibrous tissue, vascular (red
blood cells seen not within tissue matrix), or void.
Statistical analysis
As the data were nonparametric, analyses included the
Mann–Whitney U and Kruskal–Wallis as appropriate. Sig-
nificance was set at p < 0.05 and tests were analyzed with
SPSS version 24 (IBM, Chicago, IL).
Results
Influence of mobilization on fracture healing
Radiographic score showed a reduction in not united
(nonunion) and increases in uncertain and united (union)
for all groups compared with the GCSF-AMD group.
Radiographically united fractures occurred in 4/5 animals
in the PBS-AMD group, whereas this was reduced for the
VEGF, IGF, and GCSF pretreated groups with control
animals only showing a united rate in two animals out of
seven (Table 1). MicroCT analysis showed that all groups
other than GCSF-AMD had improved healing over the
controls (Table 2). PBS-AMD had twice the bone volume
(BV) within the osteotomy (8.9 – 2.2 mm3, p = 0.01), com-
pared with the untreated control (4.3 – 3.1 mm3). Not only
was the BV increased, but the overall callus tissue volume
(TV) was increased compared with controls (15.3–3.6 vs.
9.2– 6.1mm3) (Table 2; Fig. 1).
The percentage bone volume (BV/TV) was not significantly
increased owing to a relative proportional increase in bone and
nonmineralized callus tissue. In addition, the bone structure
was different in the PBS-AMD group compared with controls.
Animals in the PBS-AMD group showed a significant increase
in trabecular thickness (Tb.Th), 0.061–0.002mm compared
with those in the control group, which had a thickness of
0.042–0.003mm (p= 0.03) (Table 2; Fig. 2).
The VEGF-AMD group did not show any significant
differences from the control group. Interestingly, animals in
the GCSF-AMD group had a significant increase in BV/TV
63.1 – 7.3% versus 53.8– 20.8% ( p = 0.048), but the actual
TV (4.3 – 4.7 vs. 9.2 – 6.1 mm3) and BV (2.5 – 2.6 vs. 4.3 –
3.1 mm3) was reduced compared with controls. However,
Tb.Th was significantly higher 0.069– 0.03 versus 0.042–
0.008 mm ( p = 0.048) (Fig. 2), but total porosity (TotPor)
was significantly lower 36.9 – 7.3% versus 46.2 – 20.8%
( p = 0.048), indicating that although GCSF-AMD group
had less overall total woven bone, the bone formed was
less porous and the size of each bone forming region
within the fracture gap was larger than in controls.
Table 1. AO-ASIF Global Radiographic Healing
Score from the Mediolateral
Radiograph at 5 Weeks Postsurgery
Group Not united Uncertain United
1.5mm Control 3/7 (43%) 2/7 (29%) 2/7 (29%)
PBS-AMD 1/5 (20%) 0/5 (0%) 4/5 (80%)
VEGF-AMD 2/8 (25%) 2/8 (25%) 4/8 (50%)
GCSF-AMD 3/5 (60%) 0/0 (0%) 2/5 (40%)
IGF1-AMD 2/6 (33%) 1/6 (17%) 3/6 (50%)
GCSF, granulocyte colony stimulating factor; IGF1, insulin-like
growth factor-1; PBS, phosphate buffered saline; VEGF, vascular
endothelial growth factor.
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IGF1-AMD group also had an increase in BV (5.1–4.2mm3)
compared with controls. BV/TV was significantly increased
( p = 0.035) and the overall callus size was the same as
controls (TV 9.1 – 7.6 vs. controls 9.2 – 6.1 mm3). There
was also a significant increase in Tb.Th 0.062– 0.008mm
( p= 0.01) (Fig. 2). TotPor was significantly lower within the
fracture gap of animals treated with IGF1-AMD, compared
with controls; 40.8– 5.6% versus 46.2– 20.8% ( p= 0.035).
The spread of data was not significantly different.
When comparing between all groups, there were signifi-
cant differences in BV ( p= 0.033) (Fig. 1), Tb.Th ( p= 0.003)
(Fig. 2), TotPor ( p = 0.043), and BV/TV ( p = 0.043). All
treated groups had greater bone formation than control,
other than GCSF-AMD, which had a negative impact on
healing. However, only PBS-AMD reached statistical sig-
nificance for increased overall BV and IGF1-AMD for
percentage bone (BV/TV) within the callus. Notably, all
groups had significant increases in Tb.Th other than VEGF-
AMD. 3D reconstructed images of the representative groups
are shown in Figure 3. For full microCT quantitative mor-
phology results, see Table 2.
Histomorphometric analysis
The 2.5 · histomorphologic analysis corroborated the
microCT data; however, the differences were not statisti-
cally significant for percentage cartilage ( p = 0.053) and
percentage fibrous tissue ( p = 0.059) for the PBS-AMD
compared with controls. Patterns of increased bone forma-
tion were associated with decreased cartilage in groups with
Table 2. Microcomputed Tomography Quantitative Morphology Data from the Central
60% of the Osteotomy at 5 Weeks
1.5mm Control PBS-AMD VEGF-AMD GCSF-AMD IGF1-AMD
TV (mm3) 9.23 – 6.14 15.28 – 3.61 10.03– 3.22 4.33 – 4.72 9.08 – 7.57
BV (mm3) 4.31 – 3.08 8.916 2.16 5.22 – 1.71 2.50 – 2.60 5.11 – 4.21
TV/BV (%) 53.79 – 20.82 58.51 – 6.06 52.52– 5.85 63.076 7.29 59.246 5.58
TS (mm2) 62.83 – 45.55 60.32 – 14.75 63.56– 19.88 34.24 – 27.19 39.77 – 30.77
BS (mm2) 326.15– 220.05 450.92 – 121.44 355.52– 130.15 133.83– 147.25 269.57 – 232.90
Tb.Th (mm) 0.04 – 0.01 0.066 0.00 0.05 – 0.01 0.076 0.03 0.066 0.01
Tb.Sp (mm) 0.07 – 0.03 0.09 – 0.03 0.08 – 0.02 0.06 – 0.02 0.08 – 0.03
Tb.N (1/mm) 14.09 – 9.32 9.57 – 1.01 10.99– 1.08 10.49 – 4.88 9.71 – 1.30
TotPor (%) 46.21 – 20.82 41.49 – 6.06 47.48– 5.85 36.936 7.29 40.766 5.58
Significant results (p< 0.05) are shown in bold.
BS, bone surface area; BV, bone volume; BV/TV, percentage bone volume; TotPor, total porosity; Tb.Sp, trabecular separation; Tb.Th,
trabecular thickness; TS, tissue surface area; TV, tissue volume.
FIG. 1. The mean – SEM TV and BV
within the osteotomy measured using mi-
croCT. *Represents significant ( p < 0.05)
differences compared with 1.5mm control.
**, ***, ****, *****, and ****** indicate
significant differences ( p < 0.05) between
paired groups. BV, bone volume; GCSF,
granulocyte colony stimulating factor; IGF1,
insulin-like growth factor-1; microCT, mi-
crocomputed tomography; PBS, phosphate
buffered saline; SEM, standard error of the
mean; TV, tissue volume; VEGF, vascular
endothelial growth factor.
4 MEESON ET AL.
improved healing, whereas the worse performing groups
had an increase in fibrous tissue with decreasing bone and
cartilage formation (Fig. 4). Vascularization of the tissues
was not significantly different, although animals in the
GCSF-AMD group had the lowest levels of vasculariza-
tion, whereas groups with more bone formation had higher
levels of vascularization. However, the method of assess-
ment was relatively nonspecific, and immunohistochemistry
staining for CD31, a-SMA, or other endothelial markers
would be a means to make a more comprehensive assessment
of vascularization.
Although not quantified, the cartilage tissue present in the
GCSF-AMD group was observed to have fewer hypertro-
phic chondrocytes than the other groups (Fig. 5), suggesting
FIG. 2. The mean – SEM Tb.Th and Tb.Sp
distance of bone formed within the
osteotomy measured using microCT.
*Represents significant ( p < 0.05)
differences compared with 1.5mm control.
** and *** indicate significant differences
( p < 0.05) between different groups.
Tb.Sp, trabecular separation; Tb.Th,
trabecular thickness.
FIG. 3. MicroCT 3D re-
constructions of mid-femoral
regions, with a mid-sagittal
reveal (top row). The middle
row shows a 3D reconstruc-
tion of the central 60% of the
original osteotomy region
(180 slices). A representative
H and E stained histology
image of the central region of
the fracture is also shown.
Scale bar in lower left-hand
corner presents 500mm in all
histology images. 3D, three-
dimensional. Color images
are available online.
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reduced or slowed endochondral ossification. When com-
paring the controls to the best and worst performing groups,
the control groups had a large area of cartilage in the central
region, whereas the AMD3100 treated group had increased
woven bone, but the GCSF group had a predominance of a
highly cellular granulation type tissue (Fig. 5). The PBS-
AMD group, which had the highest levels of bone and
vascular tissue, had reduced cartilage and no fibrous tissue
(Fig. 4). However, in other groups, cartilage formation was
increased, suggesting conversion to bone by endochondral
ossification (Fig. 4). The next highest bone formation was
seen in VEGF-AMD, which also showed a low level of
fibrous tissue and higher level of vascular tissue on histo-
morphometric analysis.
Discussion
This study was the first to evaluate the potential effects
of stem/progenitor mobilization in compromised fracture
healing in rats, and demonstrated that AMD3100 antago-
nism in the early inflammatory phase of fracture healing
has a beneficial influence on bone formation. Other studies
have shown similar benefits in mice, but critically this
study allowed for direct comparison of different pretreat-
ment protocols, and for the first time demonstrated efficacy
of endogenous mobilization in a mechanically standardized
delayed union model. In this model of delayed union, there
were significant increases in bone content within the
fracture and a reduction in uncertain and not united ra-
diographic categories. This confirms that this strategy can
improve compromised fracture healing; however, because
the animals were terminated after 5 weeks, it is unclear
whether this strategy could avoid a nonunion forming.
Nonetheless, there may be translational benefit for treating
at risk groups of nonunion, such as tibial, humeral, or
clavicular fractures.27
All strategies tested other than GCSF-AMD did improve
fracture healing. AMD3100 without growth factor pretreat-
ment gave significant increases in bone formation as mea-
sured on microCT, with a bigger (proportionally mineralized)
callus compared with controls. This is similar to the findings
of Toupadakis et al.,24 who gave AMD3100 only, but over
three sequential days, rather than as a single dose. Although
not performed here due to the high complexity, parabiotic
FIG. 4. Mean – SEM percentage tissue
formed within the osteotomy from
2.5 ·magnification histomorphometry.
Color images are available online.
FIG. 5. Histology of the central region of the fracture callus (hematoxylin and eosin), showing a large area of cartilage
and hypertrophic chondrocytes adjacent to osteoid in the control; reduced cartilage, and increased woven bone formation in
the PBS-AMD group, indicating increased endochondral ossification, and a highly cellular granulation tissue in the GCSF-
AMD group. Scale bar in lower right-hand corner represents 100mm in all images. Color images are available online.
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studies with recapitulated labeled bone marrow13,14 would
offer a mechanistic understanding of the exact processes
leading to improved fracture healing.
Prior mobilization studies have shown in mice that pre-
treatment with VEGF or IGF1 preferentially increased the
numbers of MSCs mobilized into the peripheral circula-
tion.20,23 Based on these studies, we hypothesized that these
growth factors would have a greater influence on fracture
healing than giving AMD3100 alone, which comparatively
mobilizes lower levels of MSCs, EPCs, and hematopoietic
stem cells. The results of this study suggest that AMD3100
is the most effective protocol to improve fracture healing,
bringing into question whether total numbers of different
cells types, or their relative combinations, are more impor-
tant. This study shows a conclusive benefit of AMD3100,
which has been comprehensively shown to exert its main
interaction at the CXCR4 receptor,28,29 which would lead
to the release of cells that could enhance repair. However,
it is impossible to totally exclude other mechanisms
that may improve healing not due to stem/progenitor
mobilization.
An issue with measuring circulating stem/progenitor cells
is that they provide only a ‘‘snapshot’’ of the circulating
pool of cells at the predicted peak elution time of 1 h
postadministration of AMD3100.28 The duration and
character of the profile of cell elution into the circulatory
system is probably more important and so the true kinetics
of the mobilization is unknown, and hence, although VEGF
or IGF1 pretreatment before AMD3100 mobilized more
MSCs at 1 h postadministration, this does not mean the
total number is greater. It is also clear that mobilized cells
home back to the bone marrow, or indeed other tissues
such as liver, spleen, or lungs and, therefore, mobilization
has to be considered as a highly dynamic and complicated
process.30 Therefore, the only accurate evaluation of the
potential of endogenous mobilization for fracture healing is
with an in vivo fracture model.
Three mouse studies have also shown AMD3100 alone to
improve bone formation,21,22,24 and this study in a rat model
of delayed union further identifies AMD3100 along as more
effective than combining with growth factor pretreatment.
This may be due to physiological elevation of growth factors
after fracture, including VEGF and IGF1,31 or that the
mobilization profile, including cell types, timing of mobi-
lization, and total numbers of cells, is most beneficial with
AMD3100 alone. Toupadakis et al. gave three sequential
doses of AMD3100 after fracture24 and studies on the elu-
tion and pharmacokinetics of AMD3100 show that serial
administration will induce a peak mobilization at 1 h post-
treatment to the same level each time, suggesting that
receptor/system desensitization does not occur.28 This may
mean that the number of stem/progenitor cells available to
home to the fracture site could be further increased, but this
remains to be demonstrated as beneficial over a single dose.
Another consideration that has not yet been addressed is
the time of delivery of AMD3100, and presumably this has
to be associated with SDF1 release at the fracture site and
the maturity of tissue in the fracture gap. Consideration of
the effect of CXCR4 blockade at the recipient fracture site
also needs thought, as protracted treatment with AMD3100
throughout fracture healing or during distraction osteogen-
esis reduces healing.12,32 AMD3100’s short half-life of 0.9 h
in rodents18 likely underlies the benefit of short-lived
blockade early in fracture healing, as it does not persist and
inhibit ongoing migration of cells into the fracture site.
AMD3100 therapy deserves further evaluation as the route
to clinical translation is relatively simple, being already li-
censed for hematopoietic stem cell mobilization.
IGF1 pretreated groups showed the development of a
relatively more mineralized callus with a significant in-
crease in percentage bone. Kumar and Ponnazhagan23
evaluated IGF1 with AMD3100 in a mouse model and
showed a significant increase in fracture bone mineral
density on DXA scan, similar to the BV/TV in this study.
They also showed that IGF1 alone gave a moderate im-
provement in bone density, whereas AMD3100 alone did
not.23 This is in contrast with this study and the differences
may relate to peculiarities of their model and species. As
the only other group with a significant increase in bone
formation, IGF1 and AMD3100 combined may also war-
rant further investigation.
As VEGF preceding AMD3100 has previously been
demonstrated in mouse models to release the largest number
of MSCs, it was hypothesized that maximal mobilization of
these cells would be facilitated by the administration of
VEGF and this would lead to the greatest bone healing.
However, pretreatment with this growth factor did not show
a significant increase in healing unlike AMD3100 alone or
pretreatment with IGF1. This would suggest that the dif-
ferential mobilization from this combination was less ben-
eficial than the mobilization profile from AMD3100 alone.
As hypoxia and subsequent vascularization of tissues within
the fracture site plays a crucial role in progressive fracture
healing and VEGF is a potent angiogenesis promoter with a
role in endochondral and intramembranous bone forma-
tion,33,34 there was an expectation that VEGF would have
beneficial effects.
Indeed, local delivery of VEGF in rabbit mandibular defects
showed increased density of bone formation, although not the
quantity.35 Histomorphometric assessment of vascularization
was not the objective in this study, but notably the AMD3100
group had the highest number of blood vessels, although sig-
nificant differences were not detected between groups. The
VEGF pretreated group had the second highest percentage
vascularized tissue, but the significance of that is difficult to
know. In any case, there appears no significant advantage
over AMD3100 for improving bone formation.
Pretreatment with GCSF before AMD3100 reduced frac-
ture healing, which has not been previously shown. Inter-
estingly, this group had a significant increase in percentage
bone, which was indicative of a much smaller overall callus
that proportionally had a higher BV component compared
with controls. This bone region also had increased Tb.Th and
reduced porosity. All treatment groups, including GCSF-
AMD, had increased Tb.Th indicating thicker woven bone
formation, but in the GCSF-AMD group the smaller callus
had bone present that was structurally more dense. The
reduced BV may relate to the less mature chondrocytes
seen histologically, indicative of delayed endochondral
ossification, which may in turn be due to excessive in-
flammation from mobilized inflammatory cells.
Increased presence of hematopoietic lineage osteoclast
precursors, leading to bone reduction rather than deposition
is also possible. Histologically, GCSF-AMD had the lowest
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level of bone, cartilage, and vascular tissue, and the highest
level of fibrous tissue, suggesting a pattern of reduced en-
dochondral ossification, reduced blood supply, and fibrous
tissue development. Pitchford et al.20 showed that GCSF-
AMD induced mild mobilization of MSCs and EPCs, but
was principally a very effective mobilizer of hematopoietic
stem cells and neutrophils. It is possible that the increased
influx of neutrophils may have affected the progression of
inflammation at the fracture site, preventing healing. CD34+
cells, which are a particularly well-represented population
when mobilization is performed with GSCF–AMD3100, are
considered a population enriched in EPCs and hematopoietic
stem cells. Transplantation of these cells has shown improved
healing in several studies.36,37 However, this selected CD34+
population are a subset, which may explain the differences in
healing seen, compared with mixed mobilized populations
that include CD34+ cells. This has been borne out by studies
showing a mixed GCSF mobilized mononuclear cell fraction
being less efficacious than a subselected CD34+ population38
and excessive inflammation associated with the mononuclear
cell population was suggested to be the cause. One study,
however, has shown improved fracture healing with GCSF
treatment alone, given on five consecutive days. Interestingly,
their study lasted 200 days and significant differences were
not seen until at least 20–30 days, with a reduction in the
osteotomy gap distance. BV was significantly increased
from *30 days, but all rats went on to nonunion.39
In conclusion, AMD3100 significantly increased fracture
healing in a delayed union femoral model and was superior
to protocols with growth factor pretreatment. This would
suggest that peak MSC mobilization protocols previously
identified are not solely beneficial for fracture healing;
however, further study is required. In contrast, pretreat-
ment with GCSF, which preferentially mobilizes hemato-
poietic stem cells and neutrophils had a negative effect on
fracture healing and should be avoided. Further evaluation
of the timing, dose, and frequency of administration of
AMD3100 is warranted as it potentially offers a rapid route
to clinical translation.
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